Latest Research And Development News

Jindalee Lithium advances its McDermitt Lithium Project in the US with a robust 63-year Pre-Feasibility Study, enhanced permitting progress, and strong US government support under the FAST-41 initiative. Strategic partnerships and funding efforts are underway to de-risk and develop this critical mineral asset.

Orbital Corporation Ltd reported a positive operating cash flow of $0.7 million for Q1 2025, supported by a solid order book and ongoing development of a new larger capacity engine prototype.

Zelira Therapeutics has enhanced its financial flexibility through a $1.15 million R&D tax refund and a $1 million At-the-Market equity facility, while progressing FDA trial preparations for its HOPE® 1 autism treatment.

Radiopharm Theranostics has bolstered its cash position with an $8 million placement from Lantheus Holdings, now its largest shareholder. New clinical data highlight promising advances in brain metastases detection and HER2-targeted radiopharmaceutical therapies.

Streamplay Studio Limited reported a remarkable 827% increase in customer receipts for Q3 2025, driven by the full integration of Noodlecake Studios. With a robust cash balance of A$7.7 million and no debt, the company is well-positioned to accelerate growth across cloud gaming, game publishing, and emerging markets.

Critica Limited has declared a maiden Inferred Mineral Resource Estimate for its Jupiter Project, establishing it as Australia’s largest and highest-grade clay-hosted rare earth deposit. Early metallurgical testwork shows promising beneficiation results, positioning the company as a strategic player in the rare earths sector.

WA Kaolin Limited has ramped up production with new classifiers, achieving record sales and securing a $7 million capital raise, while expanding its footprint in the Chinese market.

Vection Technologies has successfully raised $3.55 million, exceeding its initial $2 million target, following a robust Q3 FY25 performance marked by a 92% increase in cash receipts and a significant boost in recurring revenue.

LTR Pharma reports strong Q1 2025 progress with FDA pre-IND meeting success, scientific acclaim for SPONTAN’s rapid absorption, and strategic launch of ROXUS to fast-track US market entry.

Mach7 Technologies reported a robust Q3 FY25 with a CARR of A$30.8 million and positive operating cash flow, while announcing a leadership change and reaffirming growth guidance.

Titomic Limited has entered a strategic teaming agreement with REPKON USA to jointly develop and apply its kinetic fusion cold spray technology for advanced defense manufacturing, focusing on repairs and performance enhancements of critical military assets.

Knosys Limited reports a record Annual Recurring Revenue run rate of $9.8 million, driven by strong enterprise renewals and new customer wins, alongside the launch of its next-generation Libero library app and upgraded LMS.